Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Sonnet BioTherapeutics Holdings (SONN)
NASDAQ:SONN
reports
Sonnet BioTherapeutics Holdings (SONN) Stock Price & Analysis
333 Followers
SONN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.91 - $9.37
Previous Close$1.06
Volume81.61K
Average Volume (3M)573.38K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$3.05M
Total Debt (Recent Filing)$255.99K
Price to Earnings (P/E)-0.2
Beta1.32
Next EarningsAug 15, 2022
EPS Estimate-$1.95
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$6.70
EPS (TTM)-6.82
Shares Outstanding7,934,156
R-Squared0.03
Standard Deviation0.20
10 Day Avg. Volume381,793
30 Day Avg. Volume573,376
Price to Book (P/B)-3.59
Price to Sales (P/S)41.97
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside549.85% Upside
Rating ConsensusModerate Buy
Alpha-0.10
Number of Analyst Covering1
Sonnet BioTherapeutics Holdings News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SONN FAQ
What was Sonnet BioTherapeutics Holdings’s price range in the past 12 months?
Sonnet BioTherapeutics Holdings lowest stock price was $0.91 and its highest was $9.37 in the past 12 months.
What is Sonnet BioTherapeutics Holdings’s market cap?
Currently, no data Available
When is Sonnet BioTherapeutics Holdings’s upcoming earnings report date?
Sonnet BioTherapeutics Holdings’s upcoming earnings report date is Aug 15, 2022 which is 176 days ago.
How were Sonnet BioTherapeutics Holdings’s earnings last quarter?
Sonnet BioTherapeutics Holdings released its earnings results on May 10, 2022. The company reported -$1.96 earnings per share for the quarter, missing the consensus estimate of -$1.723 by -$0.237.
Is Sonnet BioTherapeutics Holdings overvalued?
According to Wall Street analysts Sonnet BioTherapeutics Holdings’s price is currently Undervalued.
Does Sonnet BioTherapeutics Holdings pay dividends?
Sonnet BioTherapeutics Holdings does not currently pay dividends.
What is Sonnet BioTherapeutics Holdings’s EPS estimate?
Sonnet BioTherapeutics Holdings’s EPS estimate is -$1.95.
How many shares outstanding does Sonnet BioTherapeutics Holdings have?
Sonnet BioTherapeutics Holdings has 7,934,156 shares outstanding.
What happened to Sonnet BioTherapeutics Holdings’s price movement after its last earnings report?
Sonnet BioTherapeutics Holdings reported an EPS of -$1.96 in its last earnings report, missing expectations of -$1.723. Following the earnings report the stock price went down -9.828%.
Which hedge fund is a major shareholder of Sonnet BioTherapeutics Holdings?
Currently, no hedge funds are holding shares in SONN
---
Sonnet BioTherapeutics Holdings Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.70
$6.70
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.10%
12-Months-Change
Fundamentals
Return on Equity
-301.42%
Trailing 12-Months
Asset Growth
-79.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
---
Allarity Therapeutics, Inc.
―
CohBar
―
Hillstream BioPharma, Inc.
―
Salarius Pharmaceuticals
―
Histogen
―
---